About SynDevRx

Board of Directors

Bradley Carver, Director
Co-Founder, President, CEO SynDevRx, Inc.

Mr. Carver has over 20 years experience as a biotech senior executive. He previously served as President, CEO and Chairman of the Board of GlycoGenesys, Inc. (Russell 2000 and NASDAQ listed).  Under Mr. Carver's leadership, the company raised over $80M, successfully completed a partnership deal with a top tier pharmaceutical company, developed one of the first complex carbohydrate cancer drug candidates, and identified and characterized the mechanisms of action for their drug candidates.  He also led the clinical trial program design efforts and oversaw the selection of the clinical indications. Mr. Carver attended Michigan State University, where he received his BA in Business.

Richard L. Love, Director

Mr. Love has 40 years of industry experience, with more than 30 years of leadership roles in the biosciences industry. He started two biopharmaceutical companies, Triton Biosciences Inc. (Alameda, CA) and ILEX Oncology Inc. (ILXO, San Antonio, TX) and served as CEO in both companies for periods of eight years each. In addition Richard has served in senior executive positions at not-for-profit organizations, including the Cancer Therapy and Research Center in San Antonio, and the Translational Genomics Research Institute (TGen) in Phoenix.

At Triton and ILEX, Richard led teams that were responsible for the clinical development of four approved therapies: Betaseron® for multiple sclerosis, Fludara® and CAMPATH® both for chronic lymphocytic leukemia, and Clolar® for acute leukemias.

In 2004 ILEX was acquired by Genzyme Corporation for approximately $1B. Currently Richard is a managing partner in Translational Accelerator LLC, an Arizona-based venture capital investment firm, and also serves on the Boards of PAREXEL International (PRXL) and Cell Therapeutics (CTIC).

Eric Tooker, J.D., Director
Mr. Tooker is Executive Vice President and General Counsel of MCS Biotech Resources, which provides business, legal, administrative, and support services to expert medical consultants and start-up companies. Mr. Tooker previously served as Vice President and General Counsel for Central Newspapers, Inc. (now Gannett Co., Inc.). He has extensive experience in advising executive business teams throughout his 23-year career as in-house counsel. In that role he served as legal counsel and business adviser for a significant private equity portfolio and led mergers and acquisitions and associated bank financings. Mr. Tooker is currently a Manager of Translational Accelerator LLC (TRAC) venture fund (Scottsdale, AZ). He earned a BS degree in education from Miami University-Ohio, and a JD from the University of Michigan Law School.

James M. Shanahan, Director

Co-Founder, VP Business Development, SynDevRx, Inc.

Mr. Shanahan has over 15 years experience with business development and marketing for high tech and biotech companies.  He is a serial entrepreneur having started multiple companies.  Most recently, Jim was VP Business Development of (and continues to consult with) Ariana Pharmaceuticals, SA (Paris, France), a healthcare data intelligence company specializing in analyzing complex clinical and biomarker datasets.  Prior to that, he was co-founder and VP Marketing at JAM Technologies, Inc., where he was responsible for marketing, communications, product definition, sales and distribution initiation. Mr. Shanahan is a founding member of the French American Biotech Springboard, a non-profit group that assists French entrepreneurs with the cultural transition from an EU-based company to a US based company.  He attended the University of Massachusetts at Amherst and L'Universite Catholique de l'Ouest in Angers, France.